	US 12,274,717 B2
	PCNT as a target protein for treatment or diagnosis of brain-nervous system diseases
Minyoung Kim, Seoul (KR); and Jee In Choi, Seongnam-si (KR)
Assigned to SUNGKWANG MEDICAL FOUNDATION, Seoul (KR)
Appl. No. 16/477,443
Filed by SUNGKWANG MEDICAL FOUNDATION, Seoul (KR)
PCT Filed Jan. 11, 2018, PCT No. PCT/KR2018/000539 § 371(c)(1), (2) Date Jul. 11, 2019, PCT Pub. No. WO2018/131909, PCT Pub. Date Jul. 19, 2018.
Claims priority of application No. 10-2017-0004167 (KR), filed on Jan. 11, 2017.
Prior Publication US 2019/0336541 A1, Nov. 7, 2019
Int. Cl. A61K 35/51 (2015.01); A61K 9/00 (2006.01); A61K 38/18 (2006.01); C12Q 1/6827 (2018.01); C12Q 1/6851 (2018.01); G01N 33/50 (2006.01)

CPC A61K 35/51 (2013.01) [A61K 9/0019 (2013.01); A61K 38/18 (2013.01); C12Q 1/6827 (2013.01); C12Q 1/6851 (2013.01); G01N 33/5023 (2013.01); G01N 2500/04 (2013.01); G01N 2500/10 (2013.01)]

3 Claims

1. A method for treating a subject having central nervous system disease, the method comprising: administering to the subject an effective amount of a composition comprising:

as an active ingredient, leukocytes in cord blood expressing or secreting the amino acid sequence consisting of SEQ ID NO: 1, and erythropoietin (EPO),

wherein an expression level of the amino acid sequence consisting of SEQ ID NO: 1 is reduced in the subject having central nervous system disease before the administering the composition as compared with that of a normal individual.